Press release for the quarter and half year ended September 30, 2026.

Date of submission: October 30, 2026 To, To, The Secretary The Secretary Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Code- NH Scrip Code – 539551 (EQ), 975516 & 976418 Dear Sir/Madam, Sub: Press Release for the quarter and half year ended September 30, 2026, and Call invite With reference to the subject, please find enclosed the Press Release for the quarter and half year ended September 30, 2026 Further to our letter dated October 26, 2026, also please find attached the call invite to discuss the Company’s performance on Monday, November 02, 2026 at 03:00 P.M. (IST). Kindly take the above information on record. Thanking you Yours faithfully For Narayana Hrudayalaya Limited Sridhar S. Group Company Secretary, Legal & Compliance Officer Encl.: as above NARAYANA HRUDAYALAYA LIMITED Press Release | Q2 FY27 Results PRESS RELEASE Narayana Hrudayalaya Limited announces Q2 FY27 results Consolidated operating revenue at ₹ 28,440 Mn (YoY growth of 73.0%) with EBITDA of ₹ 6,054 Mn (YoY growth of 42.0%) Bengaluru, India, October 30th, 2026 – Narayana Hrudayalaya Limited, a leading healthcare service provider, announced its financial results for the second quarter (Q2 FY27) ended September 30th, 2026. REVENUE EBITDA PAT NET DEBT / EQUITY ₹ 28,440 Mn ₹ 6,054 Mn ₹ 3,012 Mn 0.38x +73.0% YoY · +6.0% QoQ +42.0% YoY · 21.3% margin +16.6% YoY · +45.3% QoQ Down from 0.42x at 30 Jun 2026 Q2 FY27 AT A GLANCE ■ Strong earnings growth: Consolidated EBITDA rose 42.0% YoY and 19.8% QoQ to ₹ 6,054 Mn, and PAT rose 16.6% YoY and 45.3% QoQ to ₹ 3,012 Mn. ■ Robust underlying business: Excluding the UK, revenue grew 22.6% YoY to ₹ 20,156 Mn and EBITDA grew 27.8% to ₹ 5,452 Mn, with the margin expanding to 27.0% from 25.9%. ■ India – volume, mix and margin expansion: India revenue grew 16.6% YoY, driven by higher patient volumes, complex procedures and a 75.7% rise in international patient revenue; India hospitals EBITDA margin expanded to 26.8% from 23.8% a year ago. ■ Cayman – sharp profitability improvement: Cayman EBITDA (hospital and insurance) rose to US$ 22.1 Mn from US$ 17.9 Mn a year ago, as the insurance loss narrowed to US$ 1.1 Mn from US$ 3.7 Mn in Q1 FY27. ■ Expanding capacity in core clusters: The Banashankari hospital in Bengaluru commenced operations and a 120-bed hospital at Park Street, Kolkata was added, taking the pipeline to about 1,555 beds and the bed capacity target to over 7,800. ■ Strong balance sheet: Net debt stood at ₹ 18,830 Mn as on 30 September 2026, a net debt to equity ratio of 0.38, down from 0.42 at 30 June 2026. FINANCIAL SUMMARY ₹ Mn Q2 FY27 Q2 FY26 YoY % India Revenue 14,402 12,347 16.6% Cayman Revenue (1) 6,061 4,316 40.4% UK Revenue (1) 8,284 – – Consolidated Revenue (2) 28,440 16,438 73.0% Consolidated Revenue excl. UK 20,156 16,438 22.6% Consolidated EBITDA (2) 6,054 4,265 42.0% EBITDA margin 21.3% 25.9% Consolidated EBITDA excl. UK 5,452 4,265 27.8% EBITDA margin excl. UK 27.0% 25.9% PAT 3,012 2,583 16.6% PAT margin 10.6% 15.7% Notes: (1) Cayman & UK nos. are converted from USD to INR at 95.17 for YTD FY27, and 88.31 for FY26. UK numbers are converted from GBP to USD at 1.34 for YTD FY27. The numbers may slightly vary on conversion due to different exchange rates applicable at different reporting periods. (2) Consol Revenue & EBITDA numbers are adjusted for inter-company eliminations. www.narayanahealth.org · investorrelations@narayanahealth.org Page 1 NARAYANA HRUDAYALAYA LIMITED Press Release | Q2 FY27 Results FINANCIAL HIGHLIGHTS FOR THE QUARTER Prepared in accordance with Ind AS (‘Indian Accounting Standards’). ■ Consolidated: Operating revenue was ₹ 28,440 Mn, up 73.0% YoY (largely due to the UK acquisition) and 6.0% QoQ. EBITDA was ₹ 6,054 Mn, up 42.0% YoY and 19.8% QoQ, and PAT was ₹ 3,012 Mn (10.6% margin), up 16.6% YoY and 45.3% QoQ. ■ Excluding the UK: Operating revenue was ₹ 20,156 Mn, up 8.5% QoQ, EBITDA was ₹ 5,452 Mn, up 26.1% QoQ, and PAT was ₹ 3,359 Mn (16.7% margin), up 42.6% QoQ. ■ India: Operating revenue was ₹ 14,402 Mn, up 16.6% YoY and 8.7% QoQ. EBITDA was ₹ 3,548 Mn, up 30.8% YoY and 22.3% QoQ, and PAT was ₹ 1,899 Mn (13.2% margin), up 36.2% YoY and 44.2% QoQ. ■ Cayman Islands: Operating revenue was US$ 63.4 Mn, up 28.2% YoY and 8.9% QoQ. EBITDA was US$ 22.1 Mn, up 23.8% YoY and 46.4% QoQ, and PAT was US$ 16.6 Mn (26.2% margin), up 20.9% YoY and 62.9% QoQ. ■ United Kingdom: Operating revenue was GBP 64.4 Mn, down 0.9% QoQ. EBITDA was GBP 4.7 Mn, down 18.5% QoQ, and the net loss was GBP 2.7 Mn (-4.2% PAT margin), compared with a loss of GBP 2.2 Mn in Q1 FY27. MANAGEMENT COMMENT Commenting on the performance, Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited, said: “Q2 FY27 has been a strong quarter for the Group, with consolidated EBITDA growing 42% YoY and margins improving sequentially in India and Cayman. India delivered robust growth, driven by higher patient volumes, a richer mix of high-end and complex procedures which also translated into healthy margin expansion. During the quarter, we commissioned our Banashankari hospital in Bengaluru and signed an asset-light agreement for a 120- bed hospital at Park Street, Kolkata, further strengthening our presence in our core clusters. Our Integrated Care ecosystem continues to deepen patient engagement, with clinic footfalls up over 25% YoY and improving claims experience in our insurance business. Our Cayman business continued its strong performance, with healthy growth in the hospitals business and the One Health insurance platform significantly narrowing its losses, resulting in a marked improvement in overall profitability. Our UK business delivered stable revenues, with margins reflecting near-term separation-related costs that we expect to normalize over time. We remain focused on driving operational efficiencies and growing our self- pay and insured patient business to strengthen margins. With a strong first half behind us, we thank the investor community for their continued faith and remain confident of delivering on our expectations for the year.” BUSINESS UNIT PERFORMANCE India Hospitals India revenue (excluding the ATHMA and Medha businesses, net of inter-company eliminations) was ₹ 14,388 Mn, up 16.7% YoY and 9.0% QoQ. Domestic revenue was ₹ 13,442 Mn, including ₹ 186 Mn from clinics, and international patient revenue rose to ₹ 901 Mn, up 75.7% YoY and 41.2% QoQ. By specialty, cardiac sciences remained the largest at about 33% of India hospital revenue, followed by oncology (15%), medicine and gastro sciences (14%), renal sciences (9%), neurosciences (8%) and orthopaedics (5%). By payor, self paying domestic patients contributed about 43%, insured and corporate patients 33%, government schemes (CGHS, ESIS and state schemes) 18% and international patients 7%. Operating metric – India hospitals Q2 FY27 Q2 FY26 YoY % ARPOB (₹ Mn, annualised) 19.5 17.5 11.4% Average revenue per inpatient (₹ ‘000) 163.4 149.4 9.4% Average revenue per outpatient (₹ ‘000) 5.2 4.8 7.5% Inpatient discharges (‘000) 60.5 58.3 3.7% www.narayanahealth.org · investorrelations@narayanahealth.org Page 2 NARAYANA HRUDAYALAYA LIMITED Press Release | Q2 FY27 Results Operating metric – India hospitals Q2 FY27 Q2 FY26 YoY % Hospital outpatient footfalls (‘000) 744.3 661.7 12.5% Clinic outpatient footfalls (‘000) 81.3 63.9 27.2% ICU occupied bed days (‘000) 102.3 96.3 6.2% Average length of stay (days) 4.3 4.3 – Bengaluru (NICS, MSMC, HSR) is the largest cluster at 37% of India hospital revenue, growing 18% YoY, followed by Kolkata (RTIICS, Barasat, NMH, NSH) at 26% and 16% growth. North (Gurugram, New Delhi, Jaipur) contributed 13% with 12% growth, Eastern Peripheral (Jamshedpur, Guwahati, Raipur) 10% with 16% growth, Southern Peripheral (Mysore, Shimoga, Davang [Showing first 8,000 characters — download PDF for full document]